Aigen Investment Management LP Purchases New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Aigen Investment Management LP bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,771 shares of the biopharmaceutical company’s stock, valued at approximately $546,000.

Several other large investors have also recently made changes to their positions in MDGL. Nisa Investment Advisors LLC grew its stake in shares of Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 68 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Madrigal Pharmaceuticals in the 4th quarter worth about $70,000. Quest Partners LLC raised its stake in Madrigal Pharmaceuticals by 172.8% in the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 368 shares in the last quarter. KBC Group NV raised its position in shares of Madrigal Pharmaceuticals by 73.5% during the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 258 shares in the last quarter. Finally, Miracle Mile Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the fourth quarter valued at about $216,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on MDGL shares. HC Wainwright upped their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $427.00 target price on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Citigroup upped their price objective on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, B. Riley upgraded shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and lifted their target price for the stock from $236.00 to $422.00 in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.75.

Insiders Place Their Bets

In related news, VP Robert E. Waltermire sold 1,227 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $341.07, for a total value of $418,492.89. Following the sale, the vice president now directly owns 3,728 shares of the company’s stock, valued at $1,271,508.96. This represents a 24.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Carole Huntsman sold 347 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the completion of the sale, the insider now directly owns 10,438 shares in the company, valued at approximately $3,499,235.12. The trade was a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,787 shares of company stock valued at $7,351,029 in the last quarter. Insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Price Performance

Shares of Madrigal Pharmaceuticals stock opened at $328.77 on Friday. The firm has a market cap of $7.26 billion, a PE ratio of -13.11 and a beta of -0.38. Madrigal Pharmaceuticals, Inc. has a 12-month low of $189.00 and a 12-month high of $377.46. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $324.17 and its two-hundred day simple moving average is $287.02.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.32) by $1.61. The firm had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million. As a group, equities analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.